Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison [0.03%]
补体抑制剂阿巴西普与拉珠利单抗治疗依库丽单抗失败的阵发性睡眠性血红蛋白尿患者的疗效比较：倾向匹配后的间接对比分析
Rachel H Bhak,Nikita Mody-Patel,Scott B Baver et al.
Rachel H Bhak et al.
Objective: In the absence of a head-to-head study, we assessed the comparative effectiveness of pegcetacoplan, a targeted C3 complement inhibitor, vs. ravulizumab, a C5 complement inhibitor, among patients with paroxysmal...
Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland [0.03%]
从一次性的转换到新的可重复使用的Respimat轻雾吸入器：来自瑞士的真实世界研究
Anne Tschacher,Cordula Cadus,Sebastian Schildge et al.
Anne Tschacher et al.
Objective: The aims of the survey were to assess first experiences of Swiss COPD patients switching from the disposable to the new reusable Respimat inhaler, and to evaluate physicians´ and patients´ views of the new tr...
The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018 [0.03%]
2010至2018年美国新型降糖药物的成本效益递减性分析
Piaopiao Li,Rahul Patel,Jingchuan Guo et al.
Piaopiao Li et al.
Background: The difference between the costs of the newer and older glucose-lowering drugs (GLMs) has been steadily increasing since 2010. In 2018, newer drugs cost 8-12 times more than older drugs (except for insulin). T...
Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study [0.03%]
日本偏头痛综合流行病学调查：观察性偏头痛流行病学、治疗和关怀研究（OVERCOME [日本]）的成果
Koichi Hirata,Kaname Ueda,Mika Komori et al.
Koichi Hirata et al.
Objective: The ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE study in Japan (OVERCOME [Japan]) aimed to provide an up-to-date assessment of migraine epidemiology in Japan. ...
Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study [0.03%]
美国成人注意缺陷多动障碍患者治疗模式回顾性研究
Jeff Schein,Ann Childress,Julie Adams et al.
Jeff Schein et al.
Objective: To assess treatment patterns in adults with attention-deficit/hyperactivity disorder (ADHD) and associated healthcare costs in a real-world US setting. ...
Ulcerative colitis: understanding the impact of ulcerative colitis on everyday life and exploring the unmet needs of patients [0.03%]
溃疡性结肠炎：理解溃疡性结肠炎对日常生活的影响及探索患者的未满足需求
Philip O&#x;Hagan,Jimmy Limdi,Ayesha Akbar et al.
Philip O&#x;Hagan et al.
Background: Ulcerative colitis (UC) is a life-long disease characterised by flare ups and periods of remission. This market research sponsored by Janssen-Cilag Ltd was designed to gain an understanding of the impact of UC...
Disparities in modifiable cancer risk factors among Canadian provinces, territories, and health regions [0.03%]
加拿大各省、地区和卫生局可改变的癌症危险因素差异
Omar Abdel-Rahman
Omar Abdel-Rahman
Background: Data about small area estimates of cancer risk factors are difficult to obtain in Canada. The current study aims to provide an assessment of the prevalence of different behavioral risk factors of cancer at the...
Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review [0.03%]
血管紧张素转换酶抑制剂引起的血管性水肿：一定是类效应吗？一项病例报告和简短综述
Guillaume Becker,Fabien Rougerie,Amelia-Naomi Sabo et al.
Guillaume Becker et al.
Introduction: Bradykinin-mediated angioedema is a rare but potentially fatal adverse event. Angioedema induced by angiotensin-converting enzyme (ACE) inhibitors is generally attributed to an inhibition of bradykinin degra...
An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection [0.03%]
利培酮长效注射剂单日双针起始给药方案的群体药代动力学分析：股臀和/或三角肌注射
Yanlin Wang,Xiaofeng Wang,Matt Harlin et al.
Yanlin Wang et al.
Background: The single-injection start regimen for aripiprazole once-monthly 400 mg (AOM 400) in patients with schizophrenia requires a single intramuscular injection in the gluteal or deltoid site and 14 days of concurre...
Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis [0.03%]
布洛沙zyme缓释制剂治疗轻至中度溃疡性结肠炎的有效性和安全性：系统性回顾和荟萃分析
Kristine Paridaens,John R Fullarton,Simon P L Travis
Kristine Paridaens
Background: Pentasa (prolonged-release mesalazine [5-ASA]) has been available for >30 years as an effective treatment for mild-to-moderate ulcerative colitis (UC). A systematic literature review and meta-analysis was unde...